Odyssey Therapeutics, Inc. (NASDAQ:ODTX) Receives Average Rating of “Moderate Buy” from Analysts

Odyssey Therapeutics, Inc. (NASDAQ:ODTX) has earned an average rating of “Moderate Buy” from the seven research firms that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $33.00.

Several research firms have recently weighed in on ODTX. TD Cowen began coverage on Odyssey Therapeutics in a report on Tuesday, June 2nd. They issued a “buy” rating for the company. Wall Street Zen downgraded Odyssey Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, June 20th. JPMorgan Chase & Co. lifted their price target on Odyssey Therapeutics from $26.00 to $29.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. Zacks Research upgraded Odyssey Therapeutics to a “hold” rating in a research note on Wednesday, June 3rd. Finally, Oppenheimer reissued an “outperform” rating and issued a $40.00 price objective on shares of Odyssey Therapeutics in a report on Thursday, June 18th.

Odyssey Therapeutics Trading Up 7.0%

Shares of ODTX opened at $26.39 on Friday. Odyssey Therapeutics has a 1-year low of $15.10 and a 1-year high of $26.49. The stock has a market capitalization of $1.27 billion and a PE ratio of -3.90. The company has a fifty day moving average of $18.98.

Odyssey Therapeutics (NASDAQ:ODTX) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($1.74) earnings per share (EPS) for the quarter. On average, analysts anticipate that Odyssey Therapeutics will post -5.97 earnings per share for the current fiscal year.

About Odyssey Therapeutics

Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines which are designed to precisely target disease pathology. Odyssey Therapeutics Inc is based in BOSTON.